据IFR引述消息人士报道,中国创新型制药企业恒瑞医药IPO将以44.05元上限定价,集资98.9亿元。
此前有传,恒瑞医药因新股认购需求强劲,将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉,机构投资者的认购需求已超过整个招股规模。
恒瑞医药拟全球发售2.25亿股,香港公开发售占1,234.86万股,国际发售占2.12亿股。每股招股价介乎41.45至44.05元,集资最多98.9亿元,净集资约94.58亿元。每手200股计,一手入场费8,898.85元。该股预期周五(23日)挂牌,联席保荐人为摩根士丹利、花旗及华泰国际。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.